The American Gastroenterological Association issued new guidelines on drug therapy for patients managing moderate-to-severe luminal and fistulizing Crohn’s disease.
Key recommendations center on biologic treatments, according to a May 27 news release. Biologic treatment should be used early, instead of waiting to see if other options fail, the guidelines suggest. The guidelines also say the biologic, natalizumab, is no longer recommended due to potential adverse side effects.
"We hope this new guideline serves as a manual for clinicians in selecting the right therapies for their patients, which should lead to improved patient outcomes and less need for invasive surgery," lead author Joseph Feuerstein, MD, said.
Read the full guideline published in Gastroenterology here.